Piper Sandler, Nektar
GlobalData on MSN1d
Nektar Therapeutics to sell Alabama facility to AmpersandThe transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...
On Wednesday, Nektar Therapeutics (NKTR) stock saw a decline, ending the day at $1.41 which represents a decrease of $-0.03 or -2.08% from the prior close of $1.44. The stock opened at $1.44 and ...
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...
It is wholly-owned by Nektar Therapeutics. This press release contains forward-looking statements which can be identified by words such as: "will," "can," "expect," "develop," "potential," ...
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback